{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:35:42Z","timestamp":1790487342900,"version":"4.1.0"},"reference-count":47,"publisher":"Portland Press Ltd.","issue":"22","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,11,15]]},"abstract":"<jats:p>Abdominal aortic aneurysm (AAA) evolution is unpredictable and no specific treatment exists for AAA, except surgery to prevent aortic rupture. Galectin-3 has been previously associated with CVD, but its potential role in AAA has not been addressed. Galectin-3 levels were increased in the plasma of AAA patients (n=225) compared with the control group (n=100). In addition, galectin-3 concentrations were associated with the need for surgical repair, independently of potential confounding factors. Galectin-3 mRNA and protein expression were increased in human AAA samples compared with healthy aortas. Experimental AAA in mice was induced via aortic elastase perfusion. Mice were treated intravenously with the galectin-3 inhibitor modified citrus pectin (MCP, 10 mg\/kg, every other day) or saline. Similar to humans, galectin-3 serum and aortic mRNA levels were also increased in elastase-induced AAA mice compared with control mice. Mice treated with MCP showed decreased aortic dilation, as well as elastin degradation, vascular smooth muscle cell (VSMC) loss, and macrophage content at day 14 postelastase perfusion compared with control mice. The underlying mechanism(s) of the protective effect of MCP was associated with a decrease in galectin-3 and cytokine (mainly CCL5) mRNA and protein expression. Interestingly, galectin-3 induced CCL5 expression by a mechanism involving STAT3 activation in VSMC. Accordingly, MCP treatment decreased STAT3 phosphorylation in elastase-induced AAA. In conclusion, increased galectin-3 levels are associated with AAA progression, while galectin-3 inhibition decreased experimental AAA development. Our data suggest the potential role of galectin-3 as a therapeutic target in AAA.<\/jats:p>","DOI":"10.1042\/cs20171142","type":"journal-article","created":{"date-parts":[[2017,10,6]],"date-time":"2017-10-06T00:50:19Z","timestamp":1507251019000},"page":"2707-2719","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Increased galectin-3 levels are associated with abdominal aortic aneurysm progression and inhibition of galectin-3 decreases elastase-induced AAA development"],"prefix":"10.1042","volume":"131","author":[{"given":"Carlos-Ernesto","family":"Fernandez-Garc\u00eda","sequence":"first","affiliation":[{"name":"Vascular Research Lab, FIIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz-Autonoma University, Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Tarin","sequence":"additional","affiliation":[{"name":"Vascular Research Lab, FIIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz-Autonoma University, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Roldan-Montero","sequence":"additional","affiliation":[{"name":"Vascular Research Lab, FIIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz-Autonoma University, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Martinez-Lopez","sequence":"additional","affiliation":[{"name":"Vascular Research Lab, FIIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz-Autonoma University, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Torres-Fonseca","sequence":"additional","affiliation":[{"name":"Vascular Research Lab, FIIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz-Autonoma University, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00a0S.","family":"Lindhot","sequence":"additional","affiliation":[{"name":"Department of Thoracic, Heart and Vascular Surgery University Hospital of Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina","family":"Vega de Ceniga","sequence":"additional","affiliation":[{"name":"Hospital de Galdakao, Vizcaya, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Egido","sequence":"additional","affiliation":[{"name":"Hospital Fundacion Jimenez Diaz-UAM, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Diabetes y Enfermedades Metab\u00f3licas Asociadas (CIBERDEM)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Lopez-Andres","sequence":"additional","affiliation":[{"name":"Cardiovascular translational research, Navarrabiomed\u2014Fundaci\u00f3n Miguel Servet"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis-Miguel","family":"Blanco-Colio","sequence":"additional","affiliation":[{"name":"Vascular Research Lab, FIIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz-Autonoma University, Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose-Luis","family":"Mart\u00edn-Ventura","sequence":"additional","affiliation":[{"name":"Vascular Research Lab, FIIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz-Autonoma University, Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2017,11,6]]},"reference":[{"key":"2021113010545710400_B1","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/HCO.0000000000000216","article-title":"Abdominal aortic aneurysm: novel mechanisms and therapies","volume":"30","author":"Davis","year":"2015","journal-title":"Curr. Opin. Cardiol."},{"key":"2021113010545710400_B2","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1586\/14779072.2015.1074861","article-title":"Understanding the pathogenesis of abdominal aortic aneurysms","volume":"13","author":"Kuivaniemi","year":"2015","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"2021113010545710400_B3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jvs.2016.08.003","article-title":"Challenges and opportunities in limiting abdominal aortic aneurysm growth","volume":"65","author":"Golledge","year":"2016","journal-title":"J. Vasc. Surg."},{"key":"2021113010545710400_B4","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1161\/ATVBAHA.115.306538","article-title":"Surrogate markers of abdominal aortic aneurysm progression","volume":"36","author":"Wanhainen","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021113010545710400_B5","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1017\/S1462399408000719","article-title":"Galectins: structure, function and therapeutic potential","volume":"10","author":"Yang","year":"2008","journal-title":"Expert Rev. Mol. Med."},{"key":"2021113010545710400_B6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1042\/BJ20130933","article-title":"Ligand binding and complex formation of galectin-3 is modulated by pH variations","volume":"457","author":"von Mach","year":"2014","journal-title":"Biochem. J."},{"key":"2021113010545710400_B7","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1023\/B:GLYC.0000014082.99675.2f","article-title":"Extracellular functions of galectin-3","volume":"19","author":"Ochieng","year":"2004","journal-title":"Glycoconj. J."},{"key":"2021113010545710400_B8","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1159\/000446376","article-title":"Galectin-3 in renal pathology: more than just an innocent bystander","volume":"43","author":"Desmedt","year":"2016","journal-title":"Am. J. Nephrol."},{"key":"2021113010545710400_B9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cca.2014.10.009","article-title":"Galectin-3 and heart failure: prognosis, prediction & clinical utility","volume":"443","author":"Filipe","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"2021113010545710400_B10","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ijcard.2014.12.137","article-title":"Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis","volume":"182","author":"Chen","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"2021113010545710400_B11","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ahj.2013.12.031","article-title":"Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study","volume":"167","author":"Daniels","year":"2014","journal-title":"Am. Heart J."},{"key":"2021113010545710400_B12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10557-014-6520-2","article-title":"Galectin-3: a modifiable risk factor in heart failure","volume":"28","author":"de Boer","year":"2014","journal-title":"Cardiovasc. Drugs Ther."},{"key":"2021113010545710400_B13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jchf.2014.08.002","article-title":"The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries","volume":"3","author":"Calvier","year":"2015","journal-title":"JACC Heart Fail."},{"key":"2021113010545710400_B14","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/glycob\/cwt006","article-title":"Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice","volume":"23","author":"MacKinnon","year":"2013","journal-title":"Glycobiology"},{"key":"2021113010545710400_B15","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0031-9422(01)00113-3","article-title":"Pectins: structure, biosynthesis, and oligogalacturonide-related signaling","volume":"57","author":"Ridley","year":"2001","journal-title":"Phytochemistry"},{"key":"2021113010545710400_B16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1096\/fj.08-106617","article-title":"Recognition of galactan components of pectin by galectin-3","volume":"23","author":"Gunning","year":"2009","journal-title":"FASEB J."},{"key":"2021113010545710400_B17","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/01.ATV.0000200380.73876.d9","article-title":"Reduced immunoregulatory CD31+ T cells in patients with atherosclerotic abdominal aortic aneurysm","volume":"26","author":"Caligiuri","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021113010545710400_B18","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/cvr\/cvw112","article-title":"Lipocalin-2 deficiency or blockade protects against aortic abdominal aneurysm development in mice","volume":"111","author":"Tar\u00edn","year":"2016","journal-title":"Cardiovasc. Res."},{"key":"2021113010545710400_B19","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1042\/CS20160185","article-title":"Paraoxonase-1 overexpression prevents experimental abdominal aortic aneurysm progression","volume":"130","author":"Burillo","year":"2016","journal-title":"Clin. Sci. (Lond.)"},{"key":"2021113010545710400_B20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2353\/ajpath.2008.070348","article-title":"Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice","volume":"172","author":"Nachtigal","year":"2008","journal-title":"Am. J. Pathol."},{"key":"2021113010545710400_B21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/ATVBAHA.112.300569","article-title":"Galectin-3 mediates aldosterone-induced vascular fibrosis","volume":"33","author":"Calvier","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021113010545710400_B22","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.000785","article-title":"Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis","volume":"3","author":"Madrigal-Matute","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"2021113010545710400_B23","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/eci.12605","article-title":"Soluble galectin-3 is associated with premature myocardial infarction","volume":"46","author":"Winter","year":"2016","journal-title":"Eur. J. Clin. Invest."},{"key":"2021113010545710400_B24","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jacc.2006.03.061","article-title":"Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure","volume":"48","author":"van Kimmenade","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113010545710400_B25","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1136\/heartjnl-2015-308975","article-title":"Serial galectin-3 and future cardiovascular disease in the general population","volume":"102","author":"van der Velde","year":"2016","journal-title":"Heart"},{"key":"2021113010545710400_B26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ijcard.2015.05.040","article-title":"Predictive value of galectin-3 for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort","volume":"192","author":"Jagodzinski","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"2021113010545710400_B27","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1161\/ATVBAHA.114.304964","article-title":"Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease","volume":"35","author":"Maiolino","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021113010545710400_B28","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.amjcard.2013.10.012","article-title":"Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease","volume":"113","author":"Tu\u00f1\u00f3n","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"2021113010545710400_B29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.carpath.2014.12.001","article-title":"Galectin-3 is expressed in the myocardium very early post-myocardial infarction","volume":"24","author":"Hashmi","year":"2015","journal-title":"Cardiovasc. Pathol."},{"key":"2021113010545710400_B30","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0014-5793(98)00683-8","article-title":"Galectin-3 gene (LGALS3) expression in experimental atherosclerosis and cultured smooth muscle cells","volume":"430","author":"Arar","year":"1998","journal-title":"FEBS Lett."},{"key":"2021113010545710400_B31","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1227\/01.NEU.0000365769.78334.8C","article-title":"Differential expression of genes in elastase-induced saccular aneurysms with high and low aspect ratios","volume":"66","author":"Kadirvel","year":"2010","journal-title":"Neurosurgery"},{"key":"2021113010545710400_B32","doi-asserted-by":"crossref","first-page":"13531","DOI":"10.1073\/pnas.1735526100","article-title":"Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading","volume":"100","author":"Rong","year":"2003","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021113010545710400_B33","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/cvr\/cvt206","article-title":"The galectin-3\/RAGE dyad modulates vascular osteogenesis in atherosclerosis","volume":"100","author":"Menini","year":"2013","journal-title":"Cardiovasc. Res."},{"key":"2021113010545710400_B34","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/cvr\/cvq337","article-title":"Novel aspects of the pathogenesis of aneurysms of the abdominal aorta in humans","volume":"90","author":"Michel","year":"2011","journal-title":"Cardiovasc. Res."},{"key":"2021113010545710400_B35","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/HYPERTENSIONAHA.115.06161","article-title":"Inhibition of galectin-3 pathway prevents isoproterenol-induced left ventricular dysfunction and fibrosis in mice","volume":"67","author":"Vergaro","year":"2016","journal-title":"Hypertension"},{"key":"2021113010545710400_B36","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1161\/HYPERTENSIONAHA.115.05876","article-title":"Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension","volume":"66","author":"Mart\u00ednez-Mart\u00ednez","year":"2015","journal-title":"Hypertension"},{"key":"2021113010545710400_B37","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.carres.2008.08.038","article-title":"Modified citrus pectin anti-metastatic properties: one bullet, multiple targets","volume":"344","author":"Glinsky","year":"2009","journal-title":"Carbohydr. Res."},{"key":"2021113010545710400_B38","doi-asserted-by":"crossref","first-page":"e18683","DOI":"10.1371\/journal.pone.0018683","article-title":"Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury","volume":"6","author":"Kolatsi-Joannou","year":"2011","journal-title":"PLoS ONE"},{"key":"2021113010545710400_B39","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004360","article-title":"Role for galectin-3 in calcific aortic valve stenosis","volume":"5","author":"S\u00e1daba","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"2021113010545710400_B40","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1161\/ATVBAHA.115.305269","article-title":"Inflammatory cell phenotypes in AAAs: their role and potential as targets for therapy","volume":"35","author":"Dale","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021113010545710400_B41","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1161\/CIRCULATIONAHA.111.083451","article-title":"Experimental abdominal aortic aneurysm formation is mediated by IL-17 and attenuated by mesenchymal stem cell treatment","volume":"126","author":"Sharma","year":"2012","journal-title":"Circulation"},{"key":"2021113010545710400_B42","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1161\/ATVBAHA.112.300329","article-title":"Peptide inhibitor of CXCL4-CCL5 heterodimer formation, MKEY, inhibits experimental aortic aneurysm initiation and progression","volume":"33","author":"Iida","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021113010545710400_B43","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jss.2011.05.041","article-title":"Local and systemic alterations in signal transducers and activators of transcription (STAT) associated with human abdominal aortic aneurysms","volume":"176","author":"Liao","year":"2012","journal-title":"J. Surg. Res."},{"key":"2021113010545710400_B44","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.4049\/jimmunol.165.4.2156","article-title":"Human galectin-3 is a novel chemoattractant for monocytes and macrophages","volume":"165","author":"Sano","year":"2000","journal-title":"J. Immunol."},{"key":"2021113010545710400_B45","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1002\/art.24574","article-title":"Galectin 3 induces a distinctive pattern of cytokine and chemokine production in rheumatoid synovial fibroblasts via selective signaling pathways","volume":"60","author":"Filer","year":"2009","journal-title":"Arthritis Rheum."},{"key":"2021113010545710400_B46","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/ATVBAHA.107.159160","article-title":"Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction","volume":"28","author":"Papaspyridonos","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021113010545710400_B47","doi-asserted-by":"crossref","first-page":"7037","DOI":"10.4049\/jimmunol.1000154","article-title":"Galectin-3 exerts cytokine-like regulatory actions through the JAK-STAT pathway","volume":"185","author":"Jeon","year":"2010","journal-title":"J. Immunol."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/131\/22\/2707\/446016\/cs-2017-1142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/131\/22\/2707\/446016\/cs-2017-1142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T11:46:53Z","timestamp":1638272813000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/131\/22\/2707\/71699\/Increased-galectin-3-levels-are-associated-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,6]]},"references-count":47,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2017,11,15]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20171142","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,6]]}}}